Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring.

Literature DB >> 31504796

Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring.

Francesco Pasqualetti¹, Giuliana Restante², Alessandra Gonnelli¹, Eleonora Rofi², Alessandro Molinari¹, Stefania Crucitta², Fabiola Paiar¹, Roberta Rudà³, Romano Danesi², Riccardo Soffietti³, Marzia Del Re².

Abstract

Entities: Chemical Disease Gene Mutation Species

Keywords: RAF; brain tumors; circulating free DNA; dabrafenib; exosome-derived cancer mRNA

Mesh：

Substances：

Year: 2019 PMID： 31504796 PMCID： PMC6917399 DOI： 10.1093/neuonc/noz157

Source DB: PubMed Journal: Neuro Oncol ISSN： 1522-8517 Impact factor: 12.300

× No keyword cloud information.

6 in total

1. Analysis of BRAF V600E mutation in 1,320 nervous system tumors reveals high mutation frequencies in pleomorphic xanthoastrocytoma, ganglioglioma and extra-cerebellar pilocytic astrocytoma.

Authors: Genevieve Schindler; David Capper; Jochen Meyer; Wibke Janzarik; Heymut Omran; Christel Herold-Mende; Kirsten Schmieder; Pieter Wesseling; Christian Mawrin; Martin Hasselblatt; David N Louis; Andrey Korshunov; Stefan Pfister; Christian Hartmann; Werner Paulus; Guido Reifenberger; Andreas von Deimling
Journal: Acta Neuropathol Date: 2011-01-29 Impact factor: 17.088

2. Dabrafenib in BRAFV600-mutated anaplastic pleomorphic xanthoastrocytoma.

Authors: Nicholas F Brown; Thomas Carter; Paul Mulholland
Journal: CNS Oncol Date: 2016-10-26

3. Response to the BRAF/MEK inhibitors dabrafenib/trametinib in an adolescent with a BRAF V600E mutated anaplastic ganglioglioma intolerant to vemurafenib.

Authors: Asher M Marks; Ranjit S Bindra; Michael L DiLuna; Anita Huttner; Vikram Jairam; Kristopher T Kahle; Mark W Kieran
Journal: Pediatr Blood Cancer Date: 2018-01-30 Impact factor: 3.167

Review 4. Exosomes and their implications in central nervous system tumor biology.

Authors: Oliver D Mrowczynski; Brad E Zacharia; James R Connor
Journal: Prog Neurobiol Date: 2018-07-09 Impact factor: 11.685

5. Dabrafenib in patients with recurrent, BRAF V600E mutated malignant glioma and leptomeningeal disease.

Authors: Michael C Burger; Michael W Ronellenfitsch; Nadja I Lorenz; Marlies Wagner; Martin Voss; David Capper; Theophilos Tzaridis; Ulrich Herrlinger; Joachim P Steinbach; Gabriele Stoffels; Karl-Josef Langen; Christian Brandts; Christian Senft; Patrick N Harter; Oliver Bähr
Journal: Oncol Rep Date: 2017-10-02 Impact factor: 3.906

6. BRAF Inhibition in BRAF^V600-Mutant Gliomas: Results From the VE-BASKET Study.

Authors: Thomas Kaley; Mehdi Touat; Vivek Subbiah; Antoine Hollebecque; Jordi Rodon; A Craig Lockhart; Vicki Keedy; Franck Bielle; Ralf-Dieter Hofheinz; Florence Joly; Jean-Yves Blay; Ian Chau; Igor Puzanov; Noopur S Raje; Jurgen Wolf; Lisa M DeAngelis; Martina Makrutzki; Todd Riehl; Bethany Pitcher; Jose Baselga; David M Hyman
Journal: J Clin Oncol Date: 2018-10-23 Impact factor: 44.544